Neumora Therapeutics (NMRA) Stock Price, News & Analysis

Company Overview

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease.

The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.

Neumora’s work is based in the United States, with its research aimed at addressing neurological and psychiatric conditions that affect patients broadly. Paul Berns has served as the company’s chief executive officer.

Key Stats

• Today's Range: $0.42 to $0.49
• 50-Day Range: $0.35 to $1.31
• 52-Week Range: $0.32 to $3.65
• Volume: 554,776 shs
• Average Volume: 1.72 million shs
• Market Capitalization: $80.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.57
• Consensus Rating: Moderate Buy

Neumora Therapeutics Stock Analysis - MarketRank™

Neumora Therapeutics scored higher than 59% of companies evaluated by MarketBeat, and ranked 395th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Neumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on 1 strong buy rating, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Neumora Therapeutics has a consensus price target of $6.57, representing about 1,432.2% upside from its current price of $0.43.

Amount of Analyst Coverage

Neumora Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Neumora Therapeutics are expected to grow in the coming year, from ($0.84) to ($0.59) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Neumora Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Neumora Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Neumora Therapeutics has a P/B Ratio of 0.69. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.10% of the float of Neumora Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Neumora Therapeutics has a short interest ratio ("days to cover") of 5.12.

Change versus previous month

Short interest in Neumora Therapeutics has recently increased by 24.24%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neumora Therapeutics does not currently pay a dividend.

Dividend Growth

Neumora Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.83

News Sentiment

Neumora Therapeutics has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Neumora Therapeutics this week, compared to 2 articles on an average week.

Search Interest

Only 4 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $701,219.00 in company stock.

Percentage Held by Insiders

26.94% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 11/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:NMRA
• CIK: 1885522
• Web: neumoratx.com
• Phone: 857-760-0900
• Fax: N/A
• Employees: 63
• Year Founded: 2020

Price Target and Rating

• Average Price Target for Neumora Therapeutics: $6.57
• High Price Target: $14.00
• Low Price Target: $3.00
• Potential Upside/Downside: +1,432.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.78
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$236.93 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -242.28%
• Return on Assets: -131.32%

Debt

• Debt-to-Equity Ratio: 1.19
• Current Ratio: 4.50
• Quick Ratio: 4.50

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.62 per share
• Price / Book: 0.69

Miscellaneous

• Outstanding Shares: 187,900,000
• Free Float: 137,277,000
• Market Cap: $80.59 million
• Optionable: Optionable
• Beta: 3.12